Exact Sciences Corporatio... (EXAS)
| Bid | 41.9 |
| Market Cap | 8.22B |
| Revenue (ttm) | 2.76B |
| Net Income (ttm) | -1.03B |
| EPS (ttm) | -5.59 |
| PE Ratio (ttm) | -7.92 |
| Forward PE | -158314.3 |
| Analyst | Buy |
| Ask | 47.14 |
| Volume | 823,398 |
| Avg. Volume (20D) | 2,423,693 |
| Open | 45.08 |
| Previous Close | 44.45 |
| Day's Range | 43.82 - 45.23 |
| 52-Week Range | 39.97 - 72.83 |
| Beta | 1.14 |
About EXAS
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid th...
Analyst Forecast
According to 21 analyst ratings, the average rating for EXAS stock is "Buy." The 12-month stock price forecast is $67, which is an increase of 51.41% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Exact Sciences: A Strong Q4 Reveals Signs Of A Potential Inflection PointExact Sciences posted strong Q4 revenue growth but faced a significant EPS miss due to an $838M impairment charge from the Thrive acquisition. Despite the negative market reaction, Exact's core busine...